 The European Commission EC has approved Global Blood Therapeutics Incs NASDAQ: GBT Oxbryta voxelotor for hemolytic anemia due to sickle cell disease SCD in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide hydroxyurea. Oxbryta, a once-daily, oral treatment, is the first medicine approved in Europe that directly inhibits sickle hemoglobin HbS polymerization, the molecular basis of sickling and destroying red blood cells in SCD. 